1Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretiou of B - type natriuretic peptide in comparison with those of A - type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 1994; 90 (1): 195～203
2Hystad ME. Klinge R, Spurkland A, et al. Contrasting cardiac regional responses of A - type and B - type natriuretic peptide to experimental chronic heart failure. Scand J Clin Lab Invest, 2000;60(4) :299～309
3Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation, 1993;87(2) :464～469
4Friedl W, Mair J, Thomas S, et al. Relationship between natriuretic peptides and hemodynamics in patients with heart failure at rest and after ergometric exercise. Clin Chim Acta, 1999;281(1 ～ 2):121～126
5Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end - diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 1998; 135(5 Pt 1) :825～832
6Luchner A, Muders F, Dietl O, et al. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res, 2001 Aug 15;51(3) :601～607
8Bettencourt P, Ferreira A, Dias P, et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology, 2000; 93(1～2):19～ 25
9Yamamoto K, Burnett JC Jr, Bermudes EA,et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail, 2000;6(3): 194 ～ 200
10Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B - type natriuretic peptide in the diagnosis of congestive heart failure in an ur gent - care setting. J Am Coll Cardiol,2001 ;37(2) :379～385
7[1]Cowie MR. BNP: soon to become a routine measure in the care of patients with heart failure? Heart, 2000; 83:617 ～ 618
8[2]Hobbs R. Can heart failure be diagnosed in primary care? Brain na triuretic peptide assays make it easier. BMJ, 2000; 321:188～ 189
9[5]Cohn JN, Tognoni G, Glazer RD, et al. Rationale and design of the valsartan heart failure trial: a large multinational trial to assess the ffects of valsartan, an angiotension- receptor blocker, on morbid ity and mortality in chronic congestive heart failure. J card Failure, 1999;5: 155～ 160
10[6]Darbar D, Davidson NC, Gillpesie N, et al. Diagnosic value ofB type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardial, 1996; 78: 284 ～ 287
